Leukemia: Study on the effectiveness and safety of a new treatment strategy for ruxotinib in patients with myelofibrosis anemia

Myelofibrosis (MF) is a hematological tumor, which is manifested as a disorder of the JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling pathway, which is related to normal hematopoiesis, cell growth and immune function
.

The main characteristics of MF include atypical megakaryocyte morphology, bone marrow fibrosis, anemia, splenomegaly, fatigue, weight loss, night sweats, and the risk of developing acute myeloid leukemia

Myelofibrosis (MF) is a tumor of the blood system, which is manifested as a disorder of the JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling pathway, which is related to normal hematopoiesis, cell growth and immune function

Due to age restriction and its associated high mortality rate, allogeneic stem cell transplantation is the only possible cure for MF, but it can only be applied to a small number of patients
.

Other available treatments for MF are aimed at relieving symptoms, including splenomegaly, anemia, systemic symptoms, bone pain, and symptomatic extramedullary hematopoiesis

Other available treatments for

Anemia is a common manifestation of myelofibrosis (MF), and there is still no effective treatment strategy for MF patients with anemia
.

The REALIZE Phase 2 study (NCT02966353) aims to evaluate the effectiveness and safety of a new ruxolitinib treatment strategy , which requires lowering the starting dose and delaying the infusion time in patients with anemic MF

The REALIZE Phase 2 study (NCT02966353) was designed to evaluate the effectiveness and safety of a new type of ruxolitinib treatment strategy.

Flow chart of REALIZE Phase 2 study

Flow chart of REALIZE Phase 2 study

The results showed that 51 patients with primary MF (66.
7%), post-essential thrombocythemia MF (21.
6%), or post-polycythemia vera MF (11.
8%) patients were accompanied by palpable splenomegaly and hemoglobin levels <10g /dl
.

The median age of the patients was 67 (45-88) years, 41.

Fifty-one patients with primary MF (66.

The patient's spleen status and symptom response

The patient's spleen status and symptom response

The patient received 10 mg of Ruxotinib for the first 12 weeks, and the subsequent treatment dose could be increased to 25 mg based on the efficacy and platelet count
.

The researchers found that at any time during the study, the length of the spleen that was palpable in 70% of patients was reduced by ≥50%

The most common adverse events leading to treatment dose interruption/adjustment were thrombocytopenia (17.

Cervantes, F.
, Ross, DM, Radinoff, A.
et al.
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Leukemia (20 May 2021).

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.

 

Leave a message here